Viridian Therapeutics, a biotechnology company advancing new treatments for patients suffering from serious diseases underserved by current therapies, entered into a debt financing agreement with Hercules Capital for up to $75 million.
Hercules Capital amended TG Therapeutics’ existing term loan facility agreement to increase the size of the facility to $200 million, with $70 million funded at closing.
Hercules Capital has originated more than $2 billion year to date in annual total gross debt and equity commitments, breaking its previous one-year record of $1.47 billion.
Hercules Capital, a specialty financing provider to companies backed by venture capital and select private equity firms, entered into a $100 million multi-currency credit facility with Sumitomo Mitsui Banking Corporation.
Locus Biosciences, a clinical-stage biotechnology company developing a new class of precision engineered bacteriophage treatments for bacterial and inflammatory diseases, entered a credit facility of up to $25 million with Hercules Capital.
Hercules Capital amended the existing term loan facility agreement it has with Axsome Therapeutics to increase the size of the facility to $300 million and the amount immediately available upon FDA approval of AXS-05 for major depressive disorder to $100 million at the company’s option.
Eloxx Pharmaceuticals entered into a debt facility of up to $30 million with Hercules Capital, a specialty financing lender for life science and technology companies. Eloxx has drawn the initial tranche of $12.5 million and used the proceeds to repay in full amounts outstanding under its existing debt facility.
Corium, a commercial-stage biopharmaceutical company, closed on a $235 million term loan agreement with Hercules Capital. Hercules Capital also reported it has originated more than $1.5 billion year to date in annual total gross debt and equity commitments in 2021, breaking its previous one-year record.
Phathom Pharmaceuticals, a late clinical-stage biopharmaceutical company focused on developing and commercializing novel treatments for gastrointestinal diseases, obtained a $200 million term loan facility from Hercules Capital.
Better Therapeutics, a prescription digital therapeutics company developing cognitive behavioral therapy to address the root causes of cardiometabolic diseases, secured a loan facility for up to $50 million from Hercules Capital.